论文部分内容阅读
目的观察脑心通胶囊辅治进展性缺血性脑卒中患者的临床疗效。方法将240例进展性缺血性脑卒中患者随机分为观察组与对照组各120例。对照组患者给予拜阿司匹林抗血小板聚集、瑞舒伐他汀降低血脂、稳定斑块,替米沙坦稳定血压、二甲双胍及拜唐苹降低血糖等针对危险因素进行治疗。观察组患者在对照组治疗基础上给予脑心通胶囊。比较2组临床疗效,并于治疗前后采用美国国立卫生研究院神经功能缺损程度评分(NIHSS)评价患者神经功能,并采用Barthel指数量表(BI评分)评价患者日常生活能力。结果 2组患者治疗后NIHSS评分较治疗前均有所降低,BI评分均有所升高,且观察组降低或升高幅度大于对照组,差异均有统计学意义(P<0.05)。治疗后,观察组总有效率为95.00%高于对照组的83.33%,差异有统计学意义(P<0.05)。结论脑心通胶囊可以改善进展性缺血性脑卒中患者临床神经缺损程度评分,提高患者临床治疗效果。
Objective To observe the clinical effect of Naoxintong capsule on patients with progressive ischemic stroke. Methods 240 patients with progressive ischemic stroke were randomly divided into observation group and control group of 120 cases. Patients in the control group were given anti-platelet aggregation of aspirin, rosuvastatin to reduce blood lipids, stable plaque, stable blood pressure of telmisartan, metformin, and parabutazine to reduce blood glucose and other risk factors for treatment. Patients in the observation group were given Naoxintong capsules on the basis of the control group. The clinical efficacy was compared between the two groups. Neurological function was assessed by NIHSS before and after treatment. The Barthel index scale (BI score) was used to evaluate the daily living ability of patients. Results The NIHSS scores of the two groups were lower than those before treatment, the BI scores were increased, and the decrease or increase of the observation group was greater than that of the control group (P <0.05). After treatment, the total effective rate in the observation group was 95.00%, which was significantly higher than that in the control group (83.33%, P <0.05). Conclusion Naoxintong capsule can improve the degree of clinical neurological deficits in patients with progressive ischemic stroke and improve the clinical therapeutic effect.